Clinical Trial Update: Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating the immunogenicity and safety of a dose-sparing schedule for BioThrax (anthrax vaccine adsorbed) completed with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthrax

Drugs mentioned

• BioThrax (Anthrax vaccine adsorbed)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Bacillus Anthracis (Anthrax) | Phase 4 | Status: COMPLETED | Results posted: 2014-05-28